Last reviewed · How we verify
Bioclavid
Bioclavid, marketed by The Back Research Center of Denmark, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. A key strength of Bioclavid is its established market presence, leveraging its unique mechanism to address its primary indication. The primary risk facing Bioclavid is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | Bioclavid |
|---|---|
| Sponsor | The Back Research Center, Denmark |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oral Antibiotics After Obstetric Perineal Tear (PHASE4)
- Evaluation of Antibiotic Administration Following Tooth Extraction (NA)
- Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections (PHASE4)
- Antibiotic Treatment to Patients With Low Back Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bioclavid CI brief — competitive landscape report
- Bioclavid updates RSS · CI watch RSS
- The Back Research Center, Denmark portfolio CI